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Abstract
This paper reviews methods that can be used to assess the impact of medicine use on population
health outcomes. In the absence of a gold standard, we argue that a convergence of evidence from
different types of studies using multiple methods of independent imperfection provides the best
bases for attributing improvements in health outcomes to the use of medicines. The major
requirements are: good evidence that a safe and effective medicine is being appropriately
prescribed; covariation between medicine use and improved health outcomes; and being able to
discount alternative explanations of the covariation (via covariate adjustment, propensity analyses
and sensitivity analyses), so that medicine use is the most plausible explanation of the improved
health outcomes. The strongest possible evidence would be provided by the coherence of the
following types of evidence: (1) individual linked data showing that patients are prescribed the
medicine, there are reasonable levels of patient compliance, and there is a relationship between
medicine use and health improvements that is not explained by other factors; (2) ecological
evidence of improvements in these health outcomes in the population in which the medicine is
used. Confidence in these inferences would be increased by: the replication of these results in
comparable countries and consistent trends in population vital statistics in countries that have
introduced the medicine; and epidemiological modelling indicating that changes observed in
population health outcomes are plausible given the epidemiology of the condition being treated.
Background
Many developed countries publicly subsidize selected
medicines on the assumption that their use will improve
the health of patients who take these drugs [1]. Improved
health outcomes might include: reduced incidence of dis-
ease (if medicines prevent new cases of disease in persons
at risk); reduced mortality and morbidity (if medicines are
used to treat early or established cases of a disease); and
reduced morbidity and disability or improved quality of
life (if medicines are used to slow the progression or pal-
liate the symptoms of an established disease).
Drugs are usually only subsidised if they have been shown
to be safe and effective in randomised controlled trials
(RCTs). Although data from RCTs provides good reasons
for expecting that widely prescribed medicines may
improve health outcomes, the improved health outcomes
observed in such trials may not occur in routine clinical
use. Controlled clinical trials may provide optimistic esti-
mates of effectiveness under routine clinical care because
the medicines are used to treat more seriously ill patients
in the community than were studied in clinical trials [2,3].
Drugs may also not be prescribed, they may be prescribed
Published: 15 February 2007
Australia and New Zealand Health Policy 2007, 4:1 doi:10.1186/1743-8462-4-1
Received: 25 August 2006
Accepted: 15 February 2007
This article is available from: http://www.anzhealthpolicy.com/content/4/1/1
© 2007 Hall and Lucke; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Australia and New Zealand Health Policy 2007, 4:1 http://www.anzhealthpolicy.com/content/4/1/1
Page 2 of 9
(page number not for citation purposes)
inappropriately, and patients may not comply with rec-
ommended use of the drugs.
This paper evaluates the research methods that can be
used to assess whether the use of prescribed medicines
improves health outcomes in the community. It reviews
methods used to make causal inferences about the rela-
tionships between medicine use and health outcomes
(e.g. [4,5]).
Making causal inferences
When we say that medicine use is a cause of an improved
health outcome we mean that it is a contributory cause of
the improved health outcome in the sense that use of the
medicine is one of a complex set of conditions that jointly
produced the improvement in health. In order to infer
that medicine use is a contributory cause of an improved
health outcome we need evidence that: (1) medicine use
and the health outcome covary; and (2) evidence that
makes other explanations of the relationship implausible,
leaving medicine use as a plausible contributory explana-
tion of the improved health outcome [6-8].
Assessing covariation
We can assess whether medicine use and a health out-
come covary in experiments (such as randomised control-
led trials) or in observational studies (e.g. ecological, case-
control, cohort, time series and cross-sectional studies).
Excluding alternative explanations
A and B may be correlated without being causally related.
Hence, in order to make a case for a causal relationship we
need to exclude plausible alternative explanations of the
relationship [7-9]. Experiments provide the strongest
basis for excluding alternative explanations of covariation
but they are expensive and difficult to conduct. Observa-
tional designs are easier to enact but provide a weaker
warrant for causal inferences because of their limitations
in excluding the following alternative explanations [8,10].
Chance?
We can assess the plausibility of chance by constructing a
confidence interval around the measure of covariation
between medicine use and the health outcome. If the con-
fidence interval does not include the value consistent with
the absence of a relationship between medicine use and
the health outcome, then we can infer that medicine use
and a health outcome covary [11,12].
Cause or consequence?
If medicine use is a cause of an improved health outcome,
then medicine use should occur before the improvement.
Experiments and cohort studies (which measure medicine
use before assessing the health outcome) provide the best
basis for deciding which is cause and which is conse-
quence [3].
A common cause?
If medicine use and the health outcome covary, and med-
icine use precedes the improved health outcome, we then
have to exclude the possibility that a common cause
explains the relationship between the two. Experiments
provide the best evidence against a common cause
because randomisation to an active medicine or a placebo
ensures that subjects differ only in whether or not they
have been exposed to the medicine [12,13]. When sub-
jects are randomly assigned to a medicine or a placebo
then all other causal factors will be equally distributed
between the two groups [14] and hence, any difference
between the two groups can be attributed to medicine use.
Randomisation is not infallible because there are "threats
to validity" that may arise after random assignment that
may undermine the equivalence of the two groups. There
may, for example, be differential rates of drop-out from
the two treatments, or subjects who have been assigned to
the control treatment may obtain active treatment else-
where [12,15]. If there are no such threats to validity, then
experiments provide a stronger warrant for causal infer-
ences than observational studies because the former
exclude more alternative explanations than the latter.
Causal inferences from observational data
When experiments and intervention studies cannot be
done for ethical and practical reasons common causes
must be excluded by indirect means. The logic of the
approach is conceptually straightforward: we see whether
A and B covary when possible common causes are statisti-
cally "controlled for".
One approach to this goal is to control potentially con-
founding variables in the study design. For example, we
could rule out the hypothesis that any relationship
between non-steroidal anti-inflammatory drug (NSAID)
use and coronary heart disease was a consequence of con-
current medicine use by: (i) excluding individuals with
the disease who used other medicines from a cohort
study; (ii) by matching cases and controls on concurrent
medicine use; or (iii) by stratifying potential participants
in a cohort study on confounding variables and matching
on those variables [3,16].
Another commonly used approach to dealing with con-
founding in epidemiology is covariate adjustment. In this
approach, all study participants are measured on poten-
tially confounding variables (covariates) and statistical
methods are used to estimate the association between A
and B while controlling for the covariates [16-19].Australia and New Zealand Health Policy 2007, 4:1 http://www.anzhealthpolicy.com/content/4/1/1
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Propensity score analysis can be used to assess the plausi-
bility of selection bias as an explanation of relationships
in observational studies where patients select their own
treatment [13,16]. In this approach, covariates are used to
predict the exposure condition that each individual had
the greatest propensity to receive. The resulting "propen-
sity score" can be used either as a matching variable or as
a covariate in regression analyses [13,20].
Sensitivity analyses can be used when we do not have
measures of potential confounders for covariate adjust-
ment or propensity score analysis. Such analyses explore
the plausibility of confounding as an explanation of
observed outcomes [13,16,21]. These analyses involve
modelling the relationship between medicine use and the
health outcome under various scenarios in which a con-
founding variable is related in varying degrees to both
medicine use and the outcome. If the relationship
between the two persists when allowance is made for
plausible degrees of confounding then we can be more
confident that the relationship is likely to be causal ([22],
pp 193–196).
The major limitation of all these strategies is that they can
only rule out specified alternative hypotheses. That is, we
have to identify a candidate common cause that we can
then match on, measure and adjust for using covariate
adjustment or propensity scores, or model in sensitivity
analyses. Randomisation is superior to all these strategies
because it rules out all possible common causes, includ-
ing ones that have not been measured or thought of [12].
Making causal inferences about medicine use 
and health outcomes
In making causal inferences about relationships between
health outcomes and the use of medicines we need evi-
dence that they covary, and if they do, we need to exclude
alternative explanations of the covariation, other than
that medicine use is a contributory cause of the improved
health outcome. In assessing covariation we are asking
whether there has there been a change for the better in a
health outcome that is related to medicine use. If health
outcomes have improved as medicine use has increased
then we need to assess (a) whether there is a statistically
reliable relationship between the two and if so, we need to
(b) quantify the magnitude of the relationship.
If there is an association between medicine use and
improved health outcomes, we then have to evaluate
alternative explanations of any relationship that we have
observed. If we fail to find a relationship between a popu-
lation health outcome and medicine use, we need to eval-
uate alternative explanations of why a relationship may
not have been observed before accepting the hypothesis
that medicine use failed to improve population health
outcomes.
Our capacity to make these inferences depends upon the
type of data that are available to assess covariation and the
plausibility of alternative explanations. A major distinc-
tion can be made between covariation observed in two
types of data: linked data on medicine use and health out-
comes in individuals; and aggregate data on medicine use
in a population and population health outcomes.
Casual inferences from individual data on health 
outcomes and medicine use
Ideally we would examine relationships between medi-
cine use and health outcomes in large samples of individ-
uals who comprised a representative sample of the
population about which we wish to make inferences.
These data may be collected in very large-scale special-pur-
pose longitudinal studies of representative samples of the
population (e.g. [23]), but such studies are very expensive
to mount and time-consuming to conduct [24]. Unless
they collect comprehensive data on health outcomes, they
may only able to examine the health outcomes that they
were primarily designed to study and even then they often
rely upon self-reports of both health outcomes and medi-
cine use.
An alternative approach that has been used in Canada,
Europe and the USA [25-30] is to link electronic data on
medicine use and health outcomes in identified individu-
als that is routinely collected in administrative health care
databases [31]. These linked databases typically link data
on identified individuals in separate data sets, such as,
hospital morbidity collections, mortality data, disease reg-
isters, records of outpatient care, and records of prescribed
medicines.
These data sets are usually linked without individual con-
sent because of the impracticality of obtaining it [32]. A
view often taken by research ethics committees is that
individual data can only be obtained for research pur-
poses with the consent of the person on whom the data
have been collected. This is impractical with large admin-
istrative data sets because of the costs and logistical chal-
lenges in contacting individuals and the fact that
personally contacting individuals to obtain their consent
may be arguably more intrusive than using their data
without their consent. If ethics committees insist that con-
sent is required to link individual data, then record link-
age studies cannot be done on the effects of medicine use
on health outcomes. In that case, studies of the benefits of
medicine use will be restricted to statistical analyses of
aggregate data on medicine use and health outcomes.Australia and New Zealand Health Policy 2007, 4:1 http://www.anzhealthpolicy.com/content/4/1/1
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These data sets can be linked without individual consent
if a mechanism for de-identification has been included in
the process. In Australia, for example, such data are classi-
fied as 'de-identified' and consent is no longer required for
public interest research. A protocol has been designed for
the Western Australian data linkage project to permit
health data to be linked in ways that are acceptable to eth-
ics committees and consistent with the relevant legislation
[32].
Administrative databases may not include data on patient
characteristics that predict treatment outcome [33]. Key
missing data may include: individuals' use of alcohol and
tobacco; individuals' use of over-the-counter medications;
and the presence of comorbid conditions that will affect
treatment outcome [33]. The latter may have to be
assessed indirectly via proxy indicators, such as hospital
treatment for a comorbid condition.
The major statistical challenge in studying the benefits of
medicine use via linked data is dealing with "confounding
by indication" [4,34-36]. Because patients who have par-
ticular diseases are more likely to be prescribed medicines,
those who receive the medicines usually have an higher
risk of experiencing adverse health outcomes that are
attributable to their disease, regardless of their treatment,
than patients who do not have the disease [35]. If account
is not taken of such confounding, then observational
studies may misleadingly suggest that the medicine use
produces harm when in fact it may be beneficial
[20,36,37]. The analytical approaches outlined above can
also be used to address confounding in linked data sets,
that is, covariate adjustment and analyses using propen-
sity scores, and sensitivity analyses to assess the impact of
sample selection bias on relationships between medicine
use and health outcomes [16,20,36].
The capacity of covariate adjustment and propensity anal-
ysis to adequately control for confounding by indication
depends upon the quality of data available in the database
on potential confounders, [38] and the extent of the over-
lap of distributions on key covariates between individuals
exposed to the two or more treatments that are being com-
pared [20,36]. A major limitation of both methods is that
they are only as good as the covariates that are available to
control for confounding. If key covariates that predict the
outcome (e.g. tobacco and alcohol use, comorbid condi-
tions, etc) are not measured then neither of these
approaches can be used to control for confounding by
indication [36,38]. In the absence of measures of key
potential confounders, we are limited to sensitivity analy-
ses and epidemiological modelling to assess the serious-
ness of the threat that confounding by indication poses to
the validity of any inferences that can be draw from the
data on the benefits of medicines [16].
Causal inferences from aggregate data on health 
outcomes and medicine use
When individual linked data on pharmaceutical use and
health outcomes are not available we can only assess asso-
ciations between (1) population data on pharmaceutical
use and (2) population health outcomes such as mortality
or morbidity attributable to a specific disease [5]. The
analysis of aggregate data on medicine use and health out-
come comprises a type of "ecological analysis" that uses
data on groups to make inferences about the health of
individuals [39,40]. If we assume, in the absence of good
reasons for so doing, that individual level relationships
can be inferred from aggregate level relationships, then we
are said to have committed the "ecological fallacy"
[41,42].
The dominant view in the epidemiological literature is
that ecological studies should only be conducted when
individual level data are unavailable. Even then they are
only seen as providing, at best, inexpensive and relatively
efficient ways of generating hypotheses that need to be
tested in analyses of relationships between these variables
measured in individuals (e.g. [5,10,39,43]). According to
the approach adopted here, we need to identify the major
threats to the validity of inferences from aggregate to indi-
viduals and then either design our studies to avoid them
or to analyze the data in ways that minimize these errors.
Assessing changes for the better in a health outcome
Vital statistics on population mortality and treated mor-
bidity that are collected as a standard part of public health
surveillance in most developed countries can be used to
monitor trends in population health [44,45]. Disease case
registers (e.g. of cancer mortality or incidence, cardiovas-
cular disease, diabetes) provide trend data on disease inci-
dence and prevalence for a population using standardised
criteria for defining cases. Registry data improve upon
vital statistics by producing time series data on disease
incidence or prevalence that use consistent diagnostic cri-
teria.
Trends in the prevalence of self-reported morbidity,
degree of disability and quality of life can be estimated
from periodic cross-sectional surveys of large representa-
tive samples of the population. These data provide cross-
sectional estimates of the prevalence of self-reported
health status. Sometimes they also collect data on self-
reported use of medicines [45].
Measuring medicine use in the population
Trends in medicine use can be inferred from aggregate
pharmaceutical data. These may comprise data on the
sales by volume or formulation of a specific drug or a drug
class. Sales data do not provide any information on who
is being prescribed the medicine (unless they are only pre-Australia and New Zealand Health Policy 2007, 4:1 http://www.anzhealthpolicy.com/content/4/1/1
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scribed to people within a narrow age range or to a single
sex). They also do not tell us who is having the drugs dis-
pensed and who is complying with the recommended use
of the medicines.
Data on the number of scripts that are written or dis-
pensed are closer to medicine use than sales data but they
usually do not include information on patient diagnoses
or on patient compliance. Even limited information on
the characteristics of those who are prescribed a drug
(such as age and sex) improves on aggregate prescription
data because it increases our capacity to study covariations
between population medicine exposure and population
health outcomes.
Assessing relationships between aggregate 
medicine use and health outcomes
Regression approaches
Regression models can be used to model relationships
between temporal trends in population health outcomes
and population medicine use. The strongest examples of
such analyses are those in which the design enables the
researcher to demonstrate a dose-response relationship
between medicine use within subsets of the population
and health outcomes (e.g. [46]), or between different
populations with different levels of exposure to the medi-
cines (e.g. [47]).
Interrupted time series analysis
Aggregate data on mortality and medicine use each com-
prise a time series. The health outcomes time series may
consist, for example, of monthly mortality from a specific
cause in 5-year age groups in a population over a number
of years while the medicine use time series may consist of
monthly sales data or prescription numbers for a drug or
a drug class over the same time period. Interrupted Time
Series (ITS) analysis is a set of statistical methods that can
be used to assess the impact of an intervention (such as
the introduction of a new medicine) on a health outcome
time series [48-50]. The onset of the intervention is usu-
ally specified as the date when a new drug was introduced
into a market.
A family of statistical methods can be used to analyze the
effects of an intervention on time series data while taking
account of autocorrelation: correlations between data at
different time points that invalidates conventional statis-
tical methods such as ordinary linear regression [51,52].
ITS analyses may involve using segmented linear regres-
sion methods [48,52] or Auto-regressive Integrated Mov-
ing Average (ARIMA) models [51]. More recently,
econometricians have used generalized least squares or
partial likelihood methods to fit more complex models to
time series data [49]. All such statistical methods enable
the effect of the intervention to be separated from general
trends and serial dependencies in time so that valid statis-
tical inferences can be made about whether an interven-
tion has had an effect on the time series [50].
Alternative explanations of improved population 
health outcomes
If improved population health outcomes and population
medicine use are associated, we need to assess whether the
association can be plausibly attributed to other factors. A
widely used strategy for causal inference in this situation
is quasi-experimentation [12,15]. In quasi-experimenta-
tion, the investigator first generates and then evaluates
plausible alternative explanations of the relationships that
have been observed with the aim of arriving, by a process
of elimination, at a conclusion that medicines use in the
population is the most plausible explanation of the
improved population health outcomes [12,53].
Changes in measurement
The first alternative hypothesis that needs to be consid-
ered is that changes in population health outcomes reflect
changes in the way that the health outcome has been
measured. This could occur as a result of a change in the
system of classification (e.g. the edition of the Interna-
tional Classification of Disease) that is used to code cause
of death or morbidity, a change in diagnostic criteria, or
increased attention to some causes of deaths that may
increase the apparent rate of deaths attributable to that
cause and reduce the rates of other causes of death
[12,44,48]. These possibilities need to be excluded by evi-
dence that coding systems, diagnostic criteria or medical
scrutiny have remained stable over the study period. If a
change in measurement remains a plausible hypothesis,
its effects may be assessed by sensitivity analyses.
Confounding factors
Rarely is a change in medicine use the only change that
has occurred during the period of interest that may affect
the population health outcome we are studying. Concur-
rent historical events that affect the health outcome are
another plausible hypothesis that needs to be excluded
[48]. One plausible alternative explanation is that
improved population health outcomes may reflect a
declining prevalence in the population of major risk fac-
tors for a disease. Another possibility is that changes in
population health outcomes may be due to the effects of
the increased use of other medicines or medical interven-
tions in the population.
Assessing the plausibility of alternative 
explanations
We can assess the plausibility of alternative explanations
by conducting further analyses of data and by citing sup-
portive data from other studies. If we have measures of
population exposure to other medical interventions, orAustralia and New Zealand Health Policy 2007, 4:1 http://www.anzhealthpolicy.com/content/4/1/1
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aggregate data on population trends in risk factors, we can
assess the plausibility of these explanations by regression
analyses (e.g. [54,55]). Sensitivity analyses can also be
conducted using the study data to evaluate the plausibility
of alternative explanations [16,21].
We can also look for supporting evidence from other stud-
ies. This evidence may include the absence  of similar
trends in population health outcomes in populations that
have not introduced the medicine. The presence of a sim-
ilar relationship occurring at different times in countries
that have introduced the medicine at different dates, and
its absence in countries that have not done so, reduces the
plausibility of alternative hypotheses (e.g. [47]). Our con-
fidence in the impact of medicine use on population
health outcomes will increase with replications of the
relationship between medicine use and health outcomes
in different countries which introduce the medicine at dif-
ferent times.
The role of epidemiological modelling
Epidemiological models of a disease implemented in
computer programs can be used to assess the plausibility
of alternative explanations of improvements in popula-
tion health outcomes. Macrolevel epidemiological mod-
els model the mortality of hypothetical populations (e.g.
1000 adults aged 35–39 years) from a starting age a year
at a time until a specified age (e.g. 75 years). Empirical
probabilities of experiencing different health states are
derived from population data on disease incidence and
mortality. Data from clinical trials or observational stud-
ies on the effectiveness of interventions are used to predict
the effects of interventions on mortality and morbidity in
the cohort. Markov models are used to model transitions
between different disease states over the lifetime of the
cohort of individuals [56].
Microlevel models attempt to simulate the lifetime mor-
tality experience of large samples of individuals who vary
in characteristics that predict the risk of developing a dis-
ease, dying from the disease or another cause, and
responding to interventions. These models sum the esti-
mated effects on individuals to predict the effects of inter-
ventions on population health outcomes [56]. Such
models require more knowledge of the natural history of
the disease, the effects of different interventions on its nat-
ural history, and relationships between individual charac-
teristics and disease risk and treatment outcome. They can
also be computationally complex.
Sensitivity analyses are used to assess the robustness of the
results of both types of modelling. In macro-level models,
sensitivity analyses evaluate the impact of uncertainty
about key model parameters on the model's predictions
about population health outcomes [56]. In the case of
microlevel models, sensitivity analyses assess the effects of
different starting assumptions on the results of modelling.
Epidemiological models can be used to assess the likeli-
hood that observed trends in disease incidence or mortal-
ity can be attributed to an intervention. A good example
of the utility of this type of epidemiological modelling is
provided by studies that assessed the plausibility of the
hypothesis that a decline in prostate cancer mortality in
the USA in the early 1990s was due to the widespread
adoption of prostate specific antigen (PSA) screening in
that country in the late 1980s (e.g. [57,58]).
Explaining a lack of improvement in population 
health outcomes
If there is no improvement in a population health out-
come after the introduction of a medicine we need to con-
sider a number of possible explanations for failures to
find an association [59].
First, a drug may not have been used by a large enough
proportion of the patient population to produce a detect-
able improvement in the population health outcome.
Estimates may be obtained from epidemiological model-
ling of the likely effects of medicine use on population
health outcomes for (i) varying percentages of patient cov-
erage and (ii) varying estimates of the amount by which
the efficacy observed in clinical trials is reduced in routine
clinical use.
Second, we need to consider whether our study has had
sufficient statistical power to detect improvements in
health outcomes of the size that we expect (given the
probable efficacy of the medicine and its likely patient
coverage). Statistical power will depend upon both the
size of the expected impact on population health out-
comes and the rate of increase in medicine use. It may be
difficult to detect changes in population health outcomes
if there is a slow incremental increase in medicine use. It
may be easiest to detect an effect if there is a steep, sub-
stantial and sustained increase in medicine use for a con-
dition for which no effective treatment previously existed.
Third, if a large proportion of eligible patients in the pop-
ulation are receiving the medicine we also need evidence
that the drug is being prescribed to patients who will ben-
efit from it and that these patients are taking the drug in
the required dosages with the required frequency.
Fourth, we need to consider the possible impact of coun-
tervailing factors on population health outcomes. These
may include worsening trends in risk factors that offset
any population health benefits or the effects of other med-
ications.Australia and New Zealand Health Policy 2007, 4:1 http://www.anzhealthpolicy.com/content/4/1/1
Page 7 of 9
(page number not for citation purposes)
Conclusion
There is no "gold standard" method for assessing the
impact of medicine use on health outcomes. In its
absence, a convergence of evidence from different types of
studies using multiple methods of independent imperfec-
tion provides the best reason for attributing improve-
ments in health outcomes to the use of medicines (see
table 1).
The major requirement for being able to do so is good evi-
dence that:
1. a safe and effective medicine is being appropriately pre-
scribed in clinical practice;
2. there is covariation between medicine use and
improved health outcomes;
3. we can discount alternative explanations of the covari-
ation, leaving medicine use as a plausible explanation of
the improved health outcomes.
The strongest possible evidence for an inference that the
use of a medicine has improved population health out-
comes would be provided by the coherence of the follow-
ing types of evidence:
1. Individual linked data showing that patients are pre-
scribed the medicine, there are reasonable levels of patient
compliance, and there is a relationship between medicine
use and health improvements that is not explained by
other factors;
2. Evidence of aggregate improvements in these health
outcomes in the population in which the medicine is
used;
3. The replication of these results in comparable coun-
tries;
4. Consistent trends in population vital statistics in coun-
tries that have introduced the medicine;
5. Epidemiological modelling that changes observed in
population health outcomes are plausible, given the epi-
demiology of the condition, and the clinical effectiveness
of the medicines (after discounting for the decline in effi-
cacy observed in RCTs to that expected in routine clinical
practice).
In the absence of individual linked data the next best evi-
dence comes from the coherence of the following types of
evidence:
Table 1: Approaches to studying the effects of medicines on health outcomes
Method of study Strengths Limitations
Randomised Controlled Trials and meta-
analyses of such trials
• Gold standard evidence for causal 
relationship by virtue of randomisation to 
treatment
May not predict effects of medicines on health 
outcomes because:
• May be too small to detect rare adverse 
events
• May be too short to detect long term adverse 
effects
• May exclude high risk patients e.g. those with 
comorbidity
• May involve optimal treatment and 
compliance
Linked data on individuals • Links data on medicine use and health 
outcomes in individuals
• Closer to routine clinical practice than 
evidence from RCTs
• Cheap and quick to do retrospectively
• Confounding by indication: patients who use 
medicines are at a higher risk of a disease
• Limited assessment of confounders e.g. 
comorbidity, OTC drugs, alcohol & tobacco
• Often uses treated morbidity as a proxy for 
comorbidity
Ecological studies • Simple and cheap to do because use existing 
data on medicines and health outcomes
• Directly examine relationships between 
population medicine use and health outcomes
• Use aggregate rather than individual level data
• Crude measures of medicine use e.g. drug 
sales or scripts
• Limited capacity to exclude alternative 
explanations such as changes in risk factors, 
and increased use of other treatments
Epidemiological modelling • Mathematical synthesis of epidemiological 
data on the disease and clinical trial data on 
safety and efficacy of medicines
• Simplifications of complex natural history of 
disease
• Uncertainties about long term effects of 
medicines (addressed by sensitivity analyses)
• Underdeveloped in studies of effects of 
medicines on health outcomesAustralia and New Zealand Health Policy 2007, 4:1 http://www.anzhealthpolicy.com/content/4/1/1
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1. Trends in population health outcomes that covary with
rates of exposure to the medicine in defined sub-popula-
tions (e.g. age, sex or geographic area);
2. Similar trends in comparable countries that have intro-
duced the medicine;
3. The absence of improvements in mortality in compara-
ble countries that have not introduced the medicine;
4. Evidence from epidemiological modelling that the
changes observed in population health outcomes are
plausible given the epidemiology of the condition and the
clinical effectiveness of the medicines (after discounting
for decline of efficacy in routine clinical practice).
Evidence from ecological and small observational studies
warrants less confidence in causal inference than data
from large-scale linked data sets. It may be the best that is
available if the community is unprepared to allow record
linkage in the absence of individual consent or govern-
ments are unprepared to invest in the necessary infrastruc-
ture to permit data linkage on medicines use and health
outcomes. These limitations of such data provide a strong
case for record linkage.
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